Suggested Remit: To appraise the clinical and cost effectiveness of luspatercept within its marketing authorisation for treating anaemia caused by myelodysplastic syndromes.
Status In progress
Process STA 2018
ID number 1550

Project Team

Project lead Jeremy Powell

Email enquiries

Evidence Review Group / Assessment Group School of Health and Related Research (ScHARR), University of Sheffield


Key events during the development of the guidance:

Date Update
07 November 2019 Invitation to participate
07 November 2019 In progress
28 May 2019 - 25 June 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance